CD274 and urinary bladder carcinoma: In addition, based on the treatment status and therapeutic response characteristics of bladder cancer patients receiving immunotherapy in the Tumor Immune Dysfunction and Exclusion (TIDE) database, we further found that bladder cancer patients in the high-risk group had higher scores for immune exclusion (Figure S3C), CD274 expression level, and MDSC grade than those in the low-risk group.